Novel 3-substituted-1-aryl-5-phenyl-6-anilinopyrazolo[3,4-d]pyrimidin-4-ones: Docking, synthesis and pharmacological evaluation as a potential anti-inflammatory agents

The compound 5i found to be superior to diclofenac sodium and comparable with celecoxib for anti-inflammatory activity at a dose of 25 mg/kg and showed quite less ulcerogenic potential among tested compound. The docking study revealed that compound 5i and celecoxib exhibited XP docking score −6.5485 and −5.9177, respectively.